The Fisrt Affiliated Hospital of Soochow University
Welcome,         Profile    Billing    Logout  
 93 Trials 
184 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Xiang Y
PAILACC, NCT04974346: Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer

Recruiting
3
455
RoW
Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation, Pelvic definitive concurrent chemoradiation
Zhejiang Cancer Hospital
Cervical Cancer
08/28
08/30
NCT05234905: H101 Combined With Camrelizumab for Recurrent Cervical Cancer

Not yet recruiting
2
55
RoW
Recombinant human adenovirus type 5+Camrelizumab, H101+Camrelizumab
Zhejiang Cancer Hospital
Uterine Cervical Neoplasms, Oncolytic Virotherapy, Camrelizumab
06/23
12/24
NCT05559450: Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

Recruiting
2
80
RoW
Blinatumomab, Conventional therapy
The First Affiliated Hospital of Soochow University, Fujian Medical University Union Hospital, Zhongda Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First People's Hospital of Changzhou, Wuxi People's Hospital, First Affiliated Hospital of Wannan Medical College
B-cell Acute Lymphoblastic Leukemia
01/24
01/26
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting
2
108
RoW
Envafolimab+Lenvatinib, Envafolimab
3D Medicines (Sichuan) Co., Ltd.
Advanced Endometrial Cancer
03/25
10/25
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
NCT05302206: Colonic Glucose vs. Saline Infusion

Not yet recruiting
N/A
15
RoW
colonic infusion
Qilu Hospital of Shandong University
Gastrointestinal Hormones
07/22
08/22
NCT05159323: Quantitative Assessment of Diffusion Spectrum Imaging in Breast Cancer

Recruiting
N/A
64
RoW
Diffusion Spectrum Imaging
Xiang Zhang
Breast Carcinoma; Magnetic Resonance Imaging; Diffusion Spectrum Imaging
08/22
08/22
NCT05552014: Study on the Efficacy Mechanism of Natural Psychotherapy for Neurosis

Recruiting
N/A
80
RoW
Natural Psychotherapy, Mental Health Education
Beijing HuiLongGuan Hospital
Obsessive-Compulsive Disorder
12/25
12/25
NCT05129774: Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM

Not yet recruiting
N/A
40
RoW
Radical surgery with PALND, Radical surgery without PALND
Qilu Hospital of Shandong University
Colorectal Neoplasms Malignant, Lymph Node Excision, Chemoradiotherapy
01/24
01/27
NCT06344923: Peritoneum and Anterior Rectus Sheath Suturing and Ileostomy

Recruiting
N/A
120
RoW
Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing, Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing
Qilu Hospital of Shandong University
Ileostomy - Stoma, Rectal Neoplasms
05/25
09/25
NCT05502354: CRP-guided Transanal Drainage Removal After Rectal Surgery

Recruiting
N/A
250
RoW
removal of transanal drainage tube
Qilu Hospital of Shandong University
Rectal Cancer, Anastomotic Leak
12/24
02/25
NCT06841952: Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia

Not yet recruiting
N/A
158
RoW
ATRA+Venetoclax+Azacitidine, Chemotherapy drug
The First Affiliated Hospital of Soochow University
AML, Adult
12/28
12/30
RetroBT, NCT05242861: Retrospective Study of Brachytherapy

Recruiting
N/A
300
RoW
Brachytherapy
Zhejiang Cancer Hospital
Brachytherapy, Uterine Cervical Neoplasms, Uterine Neoplasms, Vulvar Cancer, Vaginal Cancer, Ovarian Neoplasms, Gynecologic Neoplasm
12/24
12/27
NCT05571774: Construction of a Database for TTP

Recruiting
N/A
500
RoW
collection data
The First Affiliated Hospital of Soochow University
TTP - Thrombotic Thrombocytopenic Purpura
10/27
10/28
Chen, Jia Ching
DCAP, NCT04868565: Target Weaning Oxygen to Determine Cafffeine Duration for AOP

Completed
4
310
RoW
Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Children's Hospital of Chongqing Medical University
Apnea of Prematurity, Caffeine, Weaning Oxygen, Medicine Regimen
10/23
10/23
NCT02323022: Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

Completed
3
618
RoW
IAC regimen, IA regimen
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
03/20
01/22
NCT03719534: Haplo HCT vs Haplo-cord HCT for Patients With AML

Completed
3
134
RoW
haplo-HCT, haplo-cord HCT
The First Affiliated Hospital of Soochow University, Zhejiang University, The Second People's Hospital of Huai'an, Soochow Hopes Hematology Hospital, Hygeia Suzhou Yongding Hospital
Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit, Acute Myeloid Leukemia
12/22
03/23
PRECEDE, NCT06605118: Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

Recruiting
3
8000
US
Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics
The George Washington University Biostatistics Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Alabama at Birmingham
Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
11/27
03/28
PROSPECT, NCT02518594: A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix

Active, not recruiting
3
437
US
Vaginal progesterone, Prometrium, Placebo, Arabin Pessary
The George Washington University Biostatistics Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Short Cervical Length
12/24
04/25
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
NCT04686929: Abatacept s.c. for aGVHD Prevention in Haplo-HCT

Recruiting
1/2
29
RoW
Abatacept s.c.
The First Affiliated Hospital of Soochow University
Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT, Prevention
06/23
12/23
NCT03487185: Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

Recruiting
N/A
1500
US
Continuous Positive Airway Pressure, CPAP, Sleep Advice Control
The George Washington University Biostatistics Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI)
Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications
12/26
12/26
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Hepatocellular Carcinoma
03/26
03/26
Wu, Depei
NCT02323022: Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

Completed
3
618
RoW
IAC regimen, IA regimen
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
03/20
01/22
NCT03719534: Haplo HCT vs Haplo-cord HCT for Patients With AML

Completed
3
134
RoW
haplo-HCT, haplo-cord HCT
The First Affiliated Hospital of Soochow University, Zhejiang University, The Second People's Hospital of Huai'an, Soochow Hopes Hematology Hospital, Hygeia Suzhou Yongding Hospital
Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit, Acute Myeloid Leukemia
12/22
03/23
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Recruiting
3
356
RoW
Orelabrutinib and R-CHOP, R-CHOP
Beijing InnoCare Pharma Tech Co., Ltd.
Treatment-naїve Mantle Cell Lymphoma
12/24
12/27
NCT04547049: A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) from Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Recruiting
3
160
RoW
Cytarabine, Busulfan, Cyclophosphamide, Me-CCNU, Rabbit antithymocyte globulin, Allogeneic HSCT, Cyclosporin A, Mycophenolate Mofetil, MTX
First Affiliated Hospital of Zhejiang University
Leukemia
09/25
12/25
NCT05466201: The Use of Eltrombopag Post HSCT in BMFS

Recruiting
2/3
120
RoW
Eltrombopag 25 MG Oral Tablet, TPO-RA, Supportive care, support
The First Affiliated Hospital of Soochow University
Stem Cell Transplant Complications
07/25
07/27
NCT04539444: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Recruiting
2
10
RoW
CD19/22 CART, Tislelizumab, PD-1 inhibitor
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
02/22
02/23
NCT04930562: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

Completed
2
30
RoW
BN101, belumosudil, KD025
BioNova Pharmaceuticals (Shanghai) LTD.
GVHD, Chronic
06/22
12/22
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitation
2
64
RoW
ABSK021
Abbisko Therapeutics Co, Ltd
cGvHD
10/26
12/26
NCT05059912: CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

Recruiting
2
20
RoW
Humanized CD7 CAR-T cells
The First Affiliated Hospital of Soochow University, PersonGen BioTherapeutics (Suzhou) Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Affiliated Hospital of Jiangnan University, The Affiliated Zhongshan Hospital of Dalian University, The First Affiliated Hospital of Dalian Medical University
Refractory and Relapsed T Cell Lymphoma
08/23
08/24
NCT05510505: GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT

Recruiting
2
100
RoW
CD20 monoclonal antibody, allogeneic hematopoietic stem cell transplantation, ATG
The First Affiliated Hospital of Soochow University
Aplastic Anemia
09/23
12/25
NCT05182957: Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Recruiting
2
40
RoW
Anti-PD-1 monoclonal antibody, Anti-PD-1 antibody, Lenalidomide, Immunomodulator, Azacitidine, 5-Ladakamycin
The First Affiliated Hospital of Soochow University
Relapsed/Refractory Peripheral T-cell Lymphoma
12/23
12/23
NCT05322330: Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Recruiting
2
20
RoW
Selinexor, XPO-1 Inhibitor, Flu, Fludarabine, CTX, Cyclophosphamide, CAR-T, Chimeric antigen receptor-modified T (CAR-T) cell therapy
The First Affiliated Hospital of Soochow University, West China Hospital, The General Hospital of Western Theater Command PLA, The Affiliated People's Hospital of Ningbo University Ningbo Yinzhou People's Hospital Community, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Yixing People's Hospital, Affiliated Hospital of Jiangnan University, Wuxi Second People's Hospital
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
02/24
02/24
NCT06394011: Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Recruiting
2
60
RoW
venetoclax, azacitidine and HAAG regimen
The First Affiliated Hospital of Soochow University
Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
05/26
12/26
NCT05241106: A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
2
15
RoW
HYML-122
Tarapeutics Science Inc.
Relapsed or Refractory Acute Myeloid Leukemia (AML)
12/25
06/26
NCT05241093: A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
2
18
RoW
HYML-122; cytarabine
Tarapeutics Science Inc.
Relapsed or Refractory Acute Myeloid Leukemia (AML)
12/24
06/25
NCT06367114: Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

Not yet recruiting
2
50
RoW
ssCART-19, Fludarabine, Cyclophosphamide
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University, Peking University People's Hospital
Relapsed or Refractory Acute Lymphoblastic Leukemia
09/24
12/25
NCT06093841: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Active, not recruiting
2
46
RoW
Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
01/24
11/29
NCT06078306: CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

Recruiting
2
20
RoW
Azacitidine Injection, Azacitidine, Venetoclax, ABT-199, CD19CD22 CAR-T, GDC-0199
The First Affiliated Hospital of Soochow University
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia
09/24
09/25
NCT05809167: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT

Recruiting
2
55
RoW
VEN+AZA+Modified BUCY
The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia
01/25
01/26
NCT05823714: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

Recruiting
2
70
RoW
VEN+AZA+Modified BUCY
The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome
01/25
01/26
NCT05312476: Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Recruiting
2
12
RoW
Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets, Chimeric antigen receptor-modified T (CAR-T) cell therapy
The First Affiliated Hospital of Soochow University
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
02/25
02/25
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Recruiting
2
78
RoW
Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum
The First Affiliated Hospital of Soochow University
Non-GCB/ABC Diffuse Large B-Cell Lymphoma
10/25
10/25
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
NCT03455972: Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

Recruiting
1/2
15
RoW
anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs, IMiDs
The First Affiliated Hospital of Soochow University
Safety and Efficacy
12/21
12/23
AK117-103, NCT04900350: A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

Recruiting
1/2
190
RoW
AK117, Azacitidine
Akeso
Myelodysplastic Syndrome
05/23
05/24
NCT04941404: A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

Active, not recruiting
1/2
13
RoW
TQ05105 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Glucocorticoid-Refractory aGVHD
07/23
12/24
NCT05140616: Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD

Recruiting
1/2
20
RoW
Chidamide
The First Affiliated Hospital of Soochow University
Safety and Efficacy
05/24
05/24
NCT04485052: Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Suspended
1/2
222
RoW
IBI188, Azacitidine, Decitabine
Innovent Biologics (Suzhou) Co. Ltd.
Acute Myeloid Leukemia
06/24
12/24
NCT05381662: CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

Recruiting
1/2
10
RoW
CD19 CAR-T cells and CD19 positive feeder T cells
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia in Remission
08/24
12/25
NCT05647512: Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Withdrawn
1/2
380
NA
LM-305, Dexamethasone
LaNova Medicines Limited
Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases
12/24
12/25
NCT05768529: Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
1/2
100
RoW
U16
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Relapsed or Refractory Non-Hodgkin's Lymphoma
12/24
12/26
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia

Recruiting
1/2
90
RoW
BN104
BioNova Pharmaceuticals (Shanghai) LTD.
ALL, Adult, AML, Adult
06/26
06/27
NCT05148442: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Terminated
1a/1b
1
RoW
IBI322
Innovent Biologics (Suzhou) Co. Ltd.
Myeloid Tumor
06/23
08/23
NCT05270928: Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Completed
1
6
RoW
IBI346
The First Affiliated Hospital of Soochow University, Innovent Biologics (Suzhou) Co. Ltd.
Relapsed/Refractory Multiple Myeloma
12/22
05/23
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia

Not yet recruiting
1
18
RoW
IBR733 Cell Injection
Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
02/25
08/25
NCT06696833: Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Recruiting
1
18
RoW
QH10304-BAL-01, Fludarabine, Cyclophosphamide
The First Affiliated Hospital of Soochow University
B-Cell Acute Lymphoblastic Leukemia, Adult
12/25
12/25
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Completed
1
46
US, RoW
APG2575 400 mg, APG2575 600 mg, APG2575 800 mg
Ascentage Pharma Group Inc.
Waldenstrom Macroglobulinemia
02/24
02/24
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Recruiting
1
198
RoW
LP-108, Azacitidine
Guangzhou Lupeng Pharmaceutical Company LTD.
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
12/24
12/25
NCT05679687: ThisCART19A Bridging to alloHSCT for R/R B-ALL

Recruiting
1
20
RoW
Treatment
The First Affiliated Hospital of Soochow University, Fundamenta Therapeutics, Ltd.
CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL
11/25
11/25
NCT05691153: ThisCART19A for B-NHL Relapsed After Auto-CAR T

Recruiting
1
20
RoW
ThisCART19A with Dose Level 1, ThisCART19A with 2×10^6 cells/kg, ThisCART19A with Dose Level 2, ThisCART19A with 3×10^6 cells/kg
The First Affiliated Hospital of Soochow University, Fundamenta Therapeutics, Ltd.
CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
11/25
11/25
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL

Recruiting
N/A
200
RoW
Relmacabtagene Autoleucel, JWCAR029
Shanghai Ming Ju Biotechnology Co., Ltd.
Large B-cell Lymphoma
12/24
12/24
NCT05587881: Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation

Withdrawn
N/A
400
RoW
COVID-19 vaccine(donor), COVID-19 vaccine(patient)
The First Affiliated Hospital of Soochow University
Hematologic Diseases
11/23
11/23
NCT03148743: Fecal Microbiota Transplantation in Gut aGVHD Treated

Recruiting
N/A
50
RoW
Fecal microbiota
The First Affiliated Hospital of Soochow University
Acute-graft-versus-host Disease
12/25
12/25
NCT04660487: Relationship Between "FODMAPs" and "GVHD"

Recruiting
N/A
100
RoW
The First Affiliated Hospital of Soochow University
Graft Versus Host Disease
12/26
12/26
NCT06548958: A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases

Recruiting
N/A
40
RoW
Second Stem Cell Transplantation (SCT2)
The First Affiliated Hospital of Soochow University
Malignant Hematological Diseases
03/27
06/27
NCT05852028: A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Recruiting
N/A
250
RoW
Selinexor, XPO1 inhibitor
Ruijin Hospital
Lymphoma, DLBCL, T Cell Lymphoma
10/24
10/25
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting
N/A
482
RoW
Takeda
Multiple Myeloma, Neoplasms, Plasma Cell
09/25
09/25
NCT04923789: A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma

Recruiting
N/A
60
RoW
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
03/22
03/23
Sun, Aining
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
Qiu, Huiying
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
VHA, NCT05805098: Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

Recruiting
2/3
60
RoW
Venetoclax, VEN, Homoharringtonine, HHT, Cytarabine
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
03/25
03/28
NCT05951855: Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Recruiting
2
42
RoW
Selinexor, X, Chidamide, C
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia (Relapsed/Refractory)
09/24
03/25
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
Tang, Xiaowen
NCT05634915: Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation

Recruiting
4
90
RoW
Individual ATG, ATG
The First Affiliated Hospital of Soochow University
Hematopoietic Stem Cell Transplantation, Acute Leukemia
12/24
05/25
NCT04446130: Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Recruiting
3
100
RoW
Decitabine combined with HAAG Regimen
The First Affiliated Hospital of Soochow University, Henan Cancer Hospital, Shandong Provincial Hospital, Shenzhen People's Hospital, The First Affiliated Hospital of Anhui Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Changzhou No.2 People's Hospital, The Second People's Hospital of Huai'an
Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia, T-cell/Myeloid Mixed Phenotype Acute Leukemia
01/23
01/24
NCT04287660: Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Recruiting
3
20
RoW
clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
The First Affiliated Hospital of Soochow University, Changshu Frist People's Hospital, Huai'an Second People's Hospital, Affiliated Hospital of Jiangnan University, Jiangsu Province Hospital of Traditional Chinese Medicine, Jiangyin People's Hospital, Jingjiang People's Hospital, The Third People's Hospital of Kunshan, Lianyungang Hospital Affiliated Bengbu Medical College, Suzhou Municipal Hospital, Zhangjiagang First People's Hospital, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital with Nanjing Medical University, The first Affiliated Hospital of Nanjing University Medical School
Multiple Myeloma
01/23
01/25
NCT05315778: Anti-BCMA CAR T-Cell Therapy for R/R ITP

Recruiting
2
5
RoW
autologous anti-BCMA chimeric antigen receptor T cells
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
ITP
12/22
06/23
NCT05433532: Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Completed
2
20
RoW
Azacitidine, Venetoclax, Flumatinib
The First Affiliated Hospital of Soochow University
Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Mixed Phenotype Acute Leukemia
04/24
04/24
NCT04534634: Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia(R/R-ALL)

Recruiting
2
60
RoW
IFN-α combined with CAR-T cell therapy, CAR-T cell therapy
The First Affiliated Hospital of Soochow University
B-cell Acute Lymphoblastic Leukemia
07/23
07/25
NCT06578546: Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL

Recruiting
2
30
RoW
Venetoclax, Azacitidine, Orebatinib
The First Affiliated Hospital of Soochow University
Ph-Positive Acute Lymphoblastic Leukemia
02/25
02/26
NCT06394011: Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Recruiting
2
60
RoW
venetoclax, azacitidine and HAAG regimen
The First Affiliated Hospital of Soochow University
Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
05/26
12/26
NCT06393985: Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

Recruiting
2
30
RoW
Decitabine, venetoclax and blinatumomab
The First Affiliated Hospital of Soochow University
B-cell Acute Lymphoblastic Leukemia
04/26
04/27
NCT06021210: Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Recruiting
2
80
RoW
Letermovir Pill, Letermovir Tablets
The First Affiliated Hospital of Soochow University
CMV Infection, Hematopoietic Stem Cell Transplantation
07/24
09/25
NCT06078306: CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

Recruiting
2
20
RoW
Azacitidine Injection, Azacitidine, Venetoclax, ABT-199, CD19CD22 CAR-T, GDC-0199
The First Affiliated Hospital of Soochow University
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia
09/24
09/25
NCT05809167: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT

Recruiting
2
55
RoW
VEN+AZA+Modified BUCY
The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia
01/25
01/26
NCT05823714: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

Recruiting
2
70
RoW
VEN+AZA+Modified BUCY
The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome
01/25
01/26
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
NCT04351022: CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia

Recruiting
1/2
20
RoW
CART-38
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
12/21
12/23
NCT04884984: Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)

Recruiting
1/2
20
RoW
anti-CLL1 CART
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
12/22
12/24
NCT03896854: CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
1/2
15
RoW
CART-19
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Acute Myeloid Leukemia
12/24
12/25
NCT04762485: Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

Recruiting
1/2
20
RoW
Humanized CD7 CAR-T cells
The First Affiliated Hospital of Soochow University, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia
02/23
02/24
NCT04846439: Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Recruiting
1/2
20
RoW
CAR-T infusion
The First Affiliated Hospital of Soochow University, Huai'an Second People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Platelet Transfusion Refractoriness, Acute Leukemia in Remission
03/23
03/24
NCT05023707: Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1/2
5
RoW
anti-FLT3 CAR-T
The First Affiliated Hospital of Soochow University, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Huai'an Second People's Hospital, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Acute Myeloid Leukemia
06/23
06/25
NCT03275493: CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Recruiting
1/2
40
RoW
CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia, CD19 Positive, Relapse, Refractory
12/24
12/25
NCT03614858: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

Recruiting
1/2
20
RoW
CART-19/22
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University
Leukemia, B-cell
12/24
12/25
NCT05732948: PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer

Recruiting
1
12
RoW
autologous T cells & cyclophosphamide
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University
Prostate Cancer
12/24
12/24
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia

Not yet recruiting
1
18
RoW
IBR733 Cell Injection
Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
02/25
08/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Xiang Y
PAILACC, NCT04974346: Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer

Recruiting
3
455
RoW
Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation, Pelvic definitive concurrent chemoradiation
Zhejiang Cancer Hospital
Cervical Cancer
08/28
08/30
NCT05234905: H101 Combined With Camrelizumab for Recurrent Cervical Cancer

Not yet recruiting
2
55
RoW
Recombinant human adenovirus type 5+Camrelizumab, H101+Camrelizumab
Zhejiang Cancer Hospital
Uterine Cervical Neoplasms, Oncolytic Virotherapy, Camrelizumab
06/23
12/24
NCT05559450: Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

Recruiting
2
80
RoW
Blinatumomab, Conventional therapy
The First Affiliated Hospital of Soochow University, Fujian Medical University Union Hospital, Zhongda Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First People's Hospital of Changzhou, Wuxi People's Hospital, First Affiliated Hospital of Wannan Medical College
B-cell Acute Lymphoblastic Leukemia
01/24
01/26
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting
2
108
RoW
Envafolimab+Lenvatinib, Envafolimab
3D Medicines (Sichuan) Co., Ltd.
Advanced Endometrial Cancer
03/25
10/25
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
NCT05302206: Colonic Glucose vs. Saline Infusion

Not yet recruiting
N/A
15
RoW
colonic infusion
Qilu Hospital of Shandong University
Gastrointestinal Hormones
07/22
08/22
NCT05159323: Quantitative Assessment of Diffusion Spectrum Imaging in Breast Cancer

Recruiting
N/A
64
RoW
Diffusion Spectrum Imaging
Xiang Zhang
Breast Carcinoma; Magnetic Resonance Imaging; Diffusion Spectrum Imaging
08/22
08/22
NCT05552014: Study on the Efficacy Mechanism of Natural Psychotherapy for Neurosis

Recruiting
N/A
80
RoW
Natural Psychotherapy, Mental Health Education
Beijing HuiLongGuan Hospital
Obsessive-Compulsive Disorder
12/25
12/25
NCT05129774: Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM

Not yet recruiting
N/A
40
RoW
Radical surgery with PALND, Radical surgery without PALND
Qilu Hospital of Shandong University
Colorectal Neoplasms Malignant, Lymph Node Excision, Chemoradiotherapy
01/24
01/27
NCT06344923: Peritoneum and Anterior Rectus Sheath Suturing and Ileostomy

Recruiting
N/A
120
RoW
Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing, Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing
Qilu Hospital of Shandong University
Ileostomy - Stoma, Rectal Neoplasms
05/25
09/25
NCT05502354: CRP-guided Transanal Drainage Removal After Rectal Surgery

Recruiting
N/A
250
RoW
removal of transanal drainage tube
Qilu Hospital of Shandong University
Rectal Cancer, Anastomotic Leak
12/24
02/25
NCT06841952: Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia

Not yet recruiting
N/A
158
RoW
ATRA+Venetoclax+Azacitidine, Chemotherapy drug
The First Affiliated Hospital of Soochow University
AML, Adult
12/28
12/30
RetroBT, NCT05242861: Retrospective Study of Brachytherapy

Recruiting
N/A
300
RoW
Brachytherapy
Zhejiang Cancer Hospital
Brachytherapy, Uterine Cervical Neoplasms, Uterine Neoplasms, Vulvar Cancer, Vaginal Cancer, Ovarian Neoplasms, Gynecologic Neoplasm
12/24
12/27
NCT05571774: Construction of a Database for TTP

Recruiting
N/A
500
RoW
collection data
The First Affiliated Hospital of Soochow University
TTP - Thrombotic Thrombocytopenic Purpura
10/27
10/28
Chen, Jia Ching
DCAP, NCT04868565: Target Weaning Oxygen to Determine Cafffeine Duration for AOP

Completed
4
310
RoW
Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Children's Hospital of Chongqing Medical University
Apnea of Prematurity, Caffeine, Weaning Oxygen, Medicine Regimen
10/23
10/23
NCT02323022: Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

Completed
3
618
RoW
IAC regimen, IA regimen
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
03/20
01/22
NCT03719534: Haplo HCT vs Haplo-cord HCT for Patients With AML

Completed
3
134
RoW
haplo-HCT, haplo-cord HCT
The First Affiliated Hospital of Soochow University, Zhejiang University, The Second People's Hospital of Huai'an, Soochow Hopes Hematology Hospital, Hygeia Suzhou Yongding Hospital
Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit, Acute Myeloid Leukemia
12/22
03/23
PRECEDE, NCT06605118: Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

Recruiting
3
8000
US
Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics
The George Washington University Biostatistics Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Alabama at Birmingham
Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
11/27
03/28
PROSPECT, NCT02518594: A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix

Active, not recruiting
3
437
US
Vaginal progesterone, Prometrium, Placebo, Arabin Pessary
The George Washington University Biostatistics Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Short Cervical Length
12/24
04/25
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
NCT04686929: Abatacept s.c. for aGVHD Prevention in Haplo-HCT

Recruiting
1/2
29
RoW
Abatacept s.c.
The First Affiliated Hospital of Soochow University
Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT, Prevention
06/23
12/23
NCT03487185: Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

Recruiting
N/A
1500
US
Continuous Positive Airway Pressure, CPAP, Sleep Advice Control
The George Washington University Biostatistics Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI)
Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications
12/26
12/26
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Hepatocellular Carcinoma
03/26
03/26
Wu, Depei
NCT02323022: Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

Completed
3
618
RoW
IAC regimen, IA regimen
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
03/20
01/22
NCT03719534: Haplo HCT vs Haplo-cord HCT for Patients With AML

Completed
3
134
RoW
haplo-HCT, haplo-cord HCT
The First Affiliated Hospital of Soochow University, Zhejiang University, The Second People's Hospital of Huai'an, Soochow Hopes Hematology Hospital, Hygeia Suzhou Yongding Hospital
Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit, Acute Myeloid Leukemia
12/22
03/23
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Recruiting
3
356
RoW
Orelabrutinib and R-CHOP, R-CHOP
Beijing InnoCare Pharma Tech Co., Ltd.
Treatment-naїve Mantle Cell Lymphoma
12/24
12/27
NCT04547049: A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) from Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Recruiting
3
160
RoW
Cytarabine, Busulfan, Cyclophosphamide, Me-CCNU, Rabbit antithymocyte globulin, Allogeneic HSCT, Cyclosporin A, Mycophenolate Mofetil, MTX
First Affiliated Hospital of Zhejiang University
Leukemia
09/25
12/25
NCT05466201: The Use of Eltrombopag Post HSCT in BMFS

Recruiting
2/3
120
RoW
Eltrombopag 25 MG Oral Tablet, TPO-RA, Supportive care, support
The First Affiliated Hospital of Soochow University
Stem Cell Transplant Complications
07/25
07/27
NCT04539444: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Recruiting
2
10
RoW
CD19/22 CART, Tislelizumab, PD-1 inhibitor
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
02/22
02/23
NCT04930562: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

Completed
2
30
RoW
BN101, belumosudil, KD025
BioNova Pharmaceuticals (Shanghai) LTD.
GVHD, Chronic
06/22
12/22
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitation
2
64
RoW
ABSK021
Abbisko Therapeutics Co, Ltd
cGvHD
10/26
12/26
NCT05059912: CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

Recruiting
2
20
RoW
Humanized CD7 CAR-T cells
The First Affiliated Hospital of Soochow University, PersonGen BioTherapeutics (Suzhou) Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Affiliated Hospital of Jiangnan University, The Affiliated Zhongshan Hospital of Dalian University, The First Affiliated Hospital of Dalian Medical University
Refractory and Relapsed T Cell Lymphoma
08/23
08/24
NCT05510505: GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT

Recruiting
2
100
RoW
CD20 monoclonal antibody, allogeneic hematopoietic stem cell transplantation, ATG
The First Affiliated Hospital of Soochow University
Aplastic Anemia
09/23
12/25
NCT05182957: Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Recruiting
2
40
RoW
Anti-PD-1 monoclonal antibody, Anti-PD-1 antibody, Lenalidomide, Immunomodulator, Azacitidine, 5-Ladakamycin
The First Affiliated Hospital of Soochow University
Relapsed/Refractory Peripheral T-cell Lymphoma
12/23
12/23
NCT05322330: Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Recruiting
2
20
RoW
Selinexor, XPO-1 Inhibitor, Flu, Fludarabine, CTX, Cyclophosphamide, CAR-T, Chimeric antigen receptor-modified T (CAR-T) cell therapy
The First Affiliated Hospital of Soochow University, West China Hospital, The General Hospital of Western Theater Command PLA, The Affiliated People's Hospital of Ningbo University Ningbo Yinzhou People's Hospital Community, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Yixing People's Hospital, Affiliated Hospital of Jiangnan University, Wuxi Second People's Hospital
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
02/24
02/24
NCT06394011: Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Recruiting
2
60
RoW
venetoclax, azacitidine and HAAG regimen
The First Affiliated Hospital of Soochow University
Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
05/26
12/26
NCT05241106: A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
2
15
RoW
HYML-122
Tarapeutics Science Inc.
Relapsed or Refractory Acute Myeloid Leukemia (AML)
12/25
06/26
NCT05241093: A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
2
18
RoW
HYML-122; cytarabine
Tarapeutics Science Inc.
Relapsed or Refractory Acute Myeloid Leukemia (AML)
12/24
06/25
NCT06367114: Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

Not yet recruiting
2
50
RoW
ssCART-19, Fludarabine, Cyclophosphamide
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University, Peking University People's Hospital
Relapsed or Refractory Acute Lymphoblastic Leukemia
09/24
12/25
NCT06093841: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Active, not recruiting
2
46
RoW
Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
01/24
11/29
NCT06078306: CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

Recruiting
2
20
RoW
Azacitidine Injection, Azacitidine, Venetoclax, ABT-199, CD19CD22 CAR-T, GDC-0199
The First Affiliated Hospital of Soochow University
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia
09/24
09/25
NCT05809167: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT

Recruiting
2
55
RoW
VEN+AZA+Modified BUCY
The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia
01/25
01/26
NCT05823714: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

Recruiting
2
70
RoW
VEN+AZA+Modified BUCY
The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome
01/25
01/26
NCT05312476: Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Recruiting
2
12
RoW
Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets, Chimeric antigen receptor-modified T (CAR-T) cell therapy
The First Affiliated Hospital of Soochow University
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
02/25
02/25
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Recruiting
2
78
RoW
Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum
The First Affiliated Hospital of Soochow University
Non-GCB/ABC Diffuse Large B-Cell Lymphoma
10/25
10/25
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
NCT03455972: Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

Recruiting
1/2
15
RoW
anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs, IMiDs
The First Affiliated Hospital of Soochow University
Safety and Efficacy
12/21
12/23
AK117-103, NCT04900350: A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

Recruiting
1/2
190
RoW
AK117, Azacitidine
Akeso
Myelodysplastic Syndrome
05/23
05/24
NCT04941404: A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

Active, not recruiting
1/2
13
RoW
TQ05105 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Glucocorticoid-Refractory aGVHD
07/23
12/24
NCT05140616: Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD

Recruiting
1/2
20
RoW
Chidamide
The First Affiliated Hospital of Soochow University
Safety and Efficacy
05/24
05/24
NCT04485052: Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Suspended
1/2
222
RoW
IBI188, Azacitidine, Decitabine
Innovent Biologics (Suzhou) Co. Ltd.
Acute Myeloid Leukemia
06/24
12/24
NCT05381662: CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

Recruiting
1/2
10
RoW
CD19 CAR-T cells and CD19 positive feeder T cells
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia in Remission
08/24
12/25
NCT05647512: Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Withdrawn
1/2
380
NA
LM-305, Dexamethasone
LaNova Medicines Limited
Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases
12/24
12/25
NCT05768529: Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
1/2
100
RoW
U16
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Relapsed or Refractory Non-Hodgkin's Lymphoma
12/24
12/26
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia

Recruiting
1/2
90
RoW
BN104
BioNova Pharmaceuticals (Shanghai) LTD.
ALL, Adult, AML, Adult
06/26
06/27
NCT05148442: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Terminated
1a/1b
1
RoW
IBI322
Innovent Biologics (Suzhou) Co. Ltd.
Myeloid Tumor
06/23
08/23
NCT05270928: Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Completed
1
6
RoW
IBI346
The First Affiliated Hospital of Soochow University, Innovent Biologics (Suzhou) Co. Ltd.
Relapsed/Refractory Multiple Myeloma
12/22
05/23
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia

Not yet recruiting
1
18
RoW
IBR733 Cell Injection
Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
02/25
08/25
NCT06696833: Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Recruiting
1
18
RoW
QH10304-BAL-01, Fludarabine, Cyclophosphamide
The First Affiliated Hospital of Soochow University
B-Cell Acute Lymphoblastic Leukemia, Adult
12/25
12/25
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Completed
1
46
US, RoW
APG2575 400 mg, APG2575 600 mg, APG2575 800 mg
Ascentage Pharma Group Inc.
Waldenstrom Macroglobulinemia
02/24
02/24
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Recruiting
1
198
RoW
LP-108, Azacitidine
Guangzhou Lupeng Pharmaceutical Company LTD.
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
12/24
12/25
NCT05679687: ThisCART19A Bridging to alloHSCT for R/R B-ALL

Recruiting
1
20
RoW
Treatment
The First Affiliated Hospital of Soochow University, Fundamenta Therapeutics, Ltd.
CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL
11/25
11/25
NCT05691153: ThisCART19A for B-NHL Relapsed After Auto-CAR T

Recruiting
1
20
RoW
ThisCART19A with Dose Level 1, ThisCART19A with 2×10^6 cells/kg, ThisCART19A with Dose Level 2, ThisCART19A with 3×10^6 cells/kg
The First Affiliated Hospital of Soochow University, Fundamenta Therapeutics, Ltd.
CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
11/25
11/25
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL

Recruiting
N/A
200
RoW
Relmacabtagene Autoleucel, JWCAR029
Shanghai Ming Ju Biotechnology Co., Ltd.
Large B-cell Lymphoma
12/24
12/24
NCT05587881: Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation

Withdrawn
N/A
400
RoW
COVID-19 vaccine(donor), COVID-19 vaccine(patient)
The First Affiliated Hospital of Soochow University
Hematologic Diseases
11/23
11/23
NCT03148743: Fecal Microbiota Transplantation in Gut aGVHD Treated

Recruiting
N/A
50
RoW
Fecal microbiota
The First Affiliated Hospital of Soochow University
Acute-graft-versus-host Disease
12/25
12/25
NCT04660487: Relationship Between "FODMAPs" and "GVHD"

Recruiting
N/A
100
RoW
The First Affiliated Hospital of Soochow University
Graft Versus Host Disease
12/26
12/26
NCT06548958: A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases

Recruiting
N/A
40
RoW
Second Stem Cell Transplantation (SCT2)
The First Affiliated Hospital of Soochow University
Malignant Hematological Diseases
03/27
06/27
NCT05852028: A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Recruiting
N/A
250
RoW
Selinexor, XPO1 inhibitor
Ruijin Hospital
Lymphoma, DLBCL, T Cell Lymphoma
10/24
10/25
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting
N/A
482
RoW
Takeda
Multiple Myeloma, Neoplasms, Plasma Cell
09/25
09/25
NCT04923789: A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma

Recruiting
N/A
60
RoW
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
03/22
03/23
Sun, Aining
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
Qiu, Huiying
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
VHA, NCT05805098: Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

Recruiting
2/3
60
RoW
Venetoclax, VEN, Homoharringtonine, HHT, Cytarabine
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
03/25
03/28
NCT05951855: Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Recruiting
2
42
RoW
Selinexor, X, Chidamide, C
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia (Relapsed/Refractory)
09/24
03/25
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
Tang, Xiaowen
NCT05634915: Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation

Recruiting
4
90
RoW
Individual ATG, ATG
The First Affiliated Hospital of Soochow University
Hematopoietic Stem Cell Transplantation, Acute Leukemia
12/24
05/25
NCT04446130: Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Recruiting
3
100
RoW
Decitabine combined with HAAG Regimen
The First Affiliated Hospital of Soochow University, Henan Cancer Hospital, Shandong Provincial Hospital, Shenzhen People's Hospital, The First Affiliated Hospital of Anhui Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Changzhou No.2 People's Hospital, The Second People's Hospital of Huai'an
Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia, T-cell/Myeloid Mixed Phenotype Acute Leukemia
01/23
01/24
NCT04287660: Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Recruiting
3
20
RoW
clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
The First Affiliated Hospital of Soochow University, Changshu Frist People's Hospital, Huai'an Second People's Hospital, Affiliated Hospital of Jiangnan University, Jiangsu Province Hospital of Traditional Chinese Medicine, Jiangyin People's Hospital, Jingjiang People's Hospital, The Third People's Hospital of Kunshan, Lianyungang Hospital Affiliated Bengbu Medical College, Suzhou Municipal Hospital, Zhangjiagang First People's Hospital, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital with Nanjing Medical University, The first Affiliated Hospital of Nanjing University Medical School
Multiple Myeloma
01/23
01/25
NCT05315778: Anti-BCMA CAR T-Cell Therapy for R/R ITP

Recruiting
2
5
RoW
autologous anti-BCMA chimeric antigen receptor T cells
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
ITP
12/22
06/23
NCT05433532: Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Completed
2
20
RoW
Azacitidine, Venetoclax, Flumatinib
The First Affiliated Hospital of Soochow University
Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Mixed Phenotype Acute Leukemia
04/24
04/24
NCT04534634: Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia(R/R-ALL)

Recruiting
2
60
RoW
IFN-α combined with CAR-T cell therapy, CAR-T cell therapy
The First Affiliated Hospital of Soochow University
B-cell Acute Lymphoblastic Leukemia
07/23
07/25
NCT06578546: Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL

Recruiting
2
30
RoW
Venetoclax, Azacitidine, Orebatinib
The First Affiliated Hospital of Soochow University
Ph-Positive Acute Lymphoblastic Leukemia
02/25
02/26
NCT06394011: Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Recruiting
2
60
RoW
venetoclax, azacitidine and HAAG regimen
The First Affiliated Hospital of Soochow University
Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
05/26
12/26
NCT06393985: Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

Recruiting
2
30
RoW
Decitabine, venetoclax and blinatumomab
The First Affiliated Hospital of Soochow University
B-cell Acute Lymphoblastic Leukemia
04/26
04/27
NCT06021210: Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Recruiting
2
80
RoW
Letermovir Pill, Letermovir Tablets
The First Affiliated Hospital of Soochow University
CMV Infection, Hematopoietic Stem Cell Transplantation
07/24
09/25
NCT06078306: CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

Recruiting
2
20
RoW
Azacitidine Injection, Azacitidine, Venetoclax, ABT-199, CD19CD22 CAR-T, GDC-0199
The First Affiliated Hospital of Soochow University
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia
09/24
09/25
NCT05809167: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT

Recruiting
2
55
RoW
VEN+AZA+Modified BUCY
The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia
01/25
01/26
NCT05823714: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

Recruiting
2
70
RoW
VEN+AZA+Modified BUCY
The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome
01/25
01/26
SZ4601, NCT03919240: CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Active, not recruiting
1/2
196
RoW
CAR T-cell therapy
The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University
Acute Lymphoblastic Leukemia with Failed Remission
08/24
12/25
NCT04351022: CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia

Recruiting
1/2
20
RoW
CART-38
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
12/21
12/23
NCT04884984: Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)

Recruiting
1/2
20
RoW
anti-CLL1 CART
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
12/22
12/24
NCT03896854: CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
1/2
15
RoW
CART-19
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Acute Myeloid Leukemia
12/24
12/25
NCT04762485: Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

Recruiting
1/2
20
RoW
Humanized CD7 CAR-T cells
The First Affiliated Hospital of Soochow University, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia
02/23
02/24
NCT04846439: Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Recruiting
1/2
20
RoW
CAR-T infusion
The First Affiliated Hospital of Soochow University, Huai'an Second People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Platelet Transfusion Refractoriness, Acute Leukemia in Remission
03/23
03/24
NCT05023707: Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1/2
5
RoW
anti-FLT3 CAR-T
The First Affiliated Hospital of Soochow University, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Huai'an Second People's Hospital, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Acute Myeloid Leukemia
06/23
06/25
NCT03275493: CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Recruiting
1/2
40
RoW
CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia, CD19 Positive, Relapse, Refractory
12/24
12/25
NCT03614858: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

Recruiting
1/2
20
RoW
CART-19/22
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University
Leukemia, B-cell
12/24
12/25
NCT05732948: PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer

Recruiting
1
12
RoW
autologous T cells & cyclophosphamide
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University
Prostate Cancer
12/24
12/24
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia

Not yet recruiting
1
18
RoW
IBR733 Cell Injection
Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
02/25
08/25
 

Download Options